Home > Insider Trading > Filing (0001144204-18-014203)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1023024	Ani Pharmaceuticals Inc	ANIP	Pharmaceutical Preparations (2834)	582301143

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1579618	Tracy Marshbanks	C/O Ani Pharmaceuticals, Inc. 210 Main Street West Baudette MN 56623		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2018-03-08	15,391	$63.08	534,543	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2018-03-09	36,561	$63.01	497,982	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2018-03-12	12,269	$63.03	485,713	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

This transaction was executed in multiple trades at prices ranging from $63.00 to $63.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $63.00 to $63.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $63.00 to $63.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Held by FA Private Equity Fund IV, L.P., FA Private Equity Fund IV GmbH & Co. Beteiligungs KG, The Productivity Fund IV Liquidating Trust, and The Productivity Fund IV Advisors Fund Liquidating Trust, which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1)